Dexycu for postoperative inflammation after eye surgery has been approved for transitional pass-through status and reimbursement through a C-code by the CMS.
“This is a great moment for us,” Thomas Hadley, vice president of marketing and sales for EyePoint Pharmaceuticals, told Ocular Surgery News. Dexycu (dexamethasone intraocular suspension) 9% is a sustained-release alternative therapy to steroid drops that is administered through a single intraocular dose behind the iris after ocular surgery.
“CMS has approved Dexycu for transitional pass-through status, which is the
Uncategorized